Safety, pharmacokinetics and quantitative EEG modulation of TAK‐071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects

Aims TAK‐071 is a muscarinic M1 receptor positive allosteric modulator designed to have low cooperativity with acetylcholine. This was a first‐in‐human study to evaluate the safety, pharmacokinetics, and pharmacodynamics of TAK‐071. Methods TAK‐071 was administered as single and multiple doses in a...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of clinical pharmacology Vol. 88; no. 2; pp. 600 - 612
Main Authors Yin, Wei, Mamashli, Fahimeh, Buhl, Derek L., Khudyakov, Polyna, Volfson, Dmitri, Martenyi, Ferenc, Gevorkyan, Hakop, Rosen, Laura, Simen, Arthur A.
Format Journal Article
LanguageEnglish
Published England John Wiley and Sons Inc 01.02.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aims TAK‐071 is a muscarinic M1 receptor positive allosteric modulator designed to have low cooperativity with acetylcholine. This was a first‐in‐human study to evaluate the safety, pharmacokinetics, and pharmacodynamics of TAK‐071. Methods TAK‐071 was administered as single and multiple doses in a randomized, double‐blind, placebo‐controlled, parallel‐group design in healthy volunteers alone and in combination with donepezil. Laboratory, electrocardiogram (ECG) and electroencephalogram (EEG) evaluations were performed. Cerebrospinal fluid and blood samples were taken to evaluate the pharmacokinetics (PK), relative bioavailability and food effect. Results TAK‐071 was safe and well tolerated, and no deaths or serious adverse events occurred. TAK‐071 demonstrated a long mean (% coefficient of variation) half‐life of 46.3 (25.2%) to 60.5 (51.5%) hours and excellent brain penetration following oral dosing. Coadministration with donepezil had no impact on the PK of either drug. There was no food effect on systemic exposure. Quantitative EEG analysis revealed that TAK‐071 40‐80 mg increased power in the 7‐9 Hz range in the posterior electrode group with eyes open and 120‐160 mg doses increased power in the 16‐18 Hz range and reduced power in the 2‐4 Hz range in central‐posterior areas with eyes open and eyes closed. Functional connectivity was significantly reduced after TAK‐071 at high doses and was enhanced with coadministration of donepezil under the eyes‐closed condition. Conclusions PK and safety profiles of TAK‐071 were favorable, including those exceeding expected pharmacologically active doses based on preclinical data. When administered without donepezil TAK‐071 was largely free of cholinergic adverse effects. Further clinical evaluation of TAK‐071 is warranted.
AbstractList AIMSTAK-071 is a muscarinic M1 receptor positive allosteric modulator designed to have low cooperativity with acetylcholine. This was a first-in-human study to evaluate the safety, pharmacokinetics, and pharmacodynamics of TAK-071. METHODSTAK-071 was administered as single and multiple doses in a randomized, double-blind, placebo-controlled, parallel-group design in healthy volunteers alone and in combination with donepezil. Laboratory, electrocardiogram (ECG) and electroencephalogram (EEG) evaluations were performed. Cerebrospinal fluid and blood samples were taken to evaluate the pharmacokinetics (PK), relative bioavailability and food effect. RESULTSTAK-071 was safe and well tolerated, and no deaths or serious adverse events occurred. TAK-071 demonstrated a long mean (% coefficient of variation) half-life of 46.3 (25.2%) to 60.5 (51.5%) hours and excellent brain penetration following oral dosing. Coadministration with donepezil had no impact on the PK of either drug. There was no food effect on systemic exposure. Quantitative EEG analysis revealed that TAK-071 40-80 mg increased power in the 7-9 Hz range in the posterior electrode group with eyes open and 120-160 mg doses increased power in the 16-18 Hz range and reduced power in the 2-4 Hz range in central-posterior areas with eyes open and eyes closed. Functional connectivity was significantly reduced after TAK-071 at high doses and was enhanced with coadministration of donepezil under the eyes-closed condition. CONCLUSIONSPK and safety profiles of TAK-071 were favorable, including those exceeding expected pharmacologically active doses based on preclinical data. When administered without donepezil TAK-071 was largely free of cholinergic adverse effects. Further clinical evaluation of TAK-071 is warranted.
Aims TAK‐071 is a muscarinic M1 receptor positive allosteric modulator designed to have low cooperativity with acetylcholine. This was a first‐in‐human study to evaluate the safety, pharmacokinetics, and pharmacodynamics of TAK‐071. Methods TAK‐071 was administered as single and multiple doses in a randomized, double‐blind, placebo‐controlled, parallel‐group design in healthy volunteers alone and in combination with donepezil. Laboratory, electrocardiogram (ECG) and electroencephalogram (EEG) evaluations were performed. Cerebrospinal fluid and blood samples were taken to evaluate the pharmacokinetics (PK), relative bioavailability and food effect. Results TAK‐071 was safe and well tolerated, and no deaths or serious adverse events occurred. TAK‐071 demonstrated a long mean (% coefficient of variation) half‐life of 46.3 (25.2%) to 60.5 (51.5%) hours and excellent brain penetration following oral dosing. Coadministration with donepezil had no impact on the PK of either drug. There was no food effect on systemic exposure. Quantitative EEG analysis revealed that TAK‐071 40‐80 mg increased power in the 7‐9 Hz range in the posterior electrode group with eyes open and 120‐160 mg doses increased power in the 16‐18 Hz range and reduced power in the 2‐4 Hz range in central‐posterior areas with eyes open and eyes closed. Functional connectivity was significantly reduced after TAK‐071 at high doses and was enhanced with coadministration of donepezil under the eyes‐closed condition. Conclusions PK and safety profiles of TAK‐071 were favorable, including those exceeding expected pharmacologically active doses based on preclinical data. When administered without donepezil TAK‐071 was largely free of cholinergic adverse effects. Further clinical evaluation of TAK‐071 is warranted.
TAK-071 is a muscarinic M receptor positive allosteric modulator designed to have low cooperativity with acetylcholine. This was a first-in-human study to evaluate the safety, pharmacokinetics, and pharmacodynamics of TAK-071. TAK-071 was administered as single and multiple doses in a randomized, double-blind, placebo-controlled, parallel-group design in healthy volunteers alone and in combination with donepezil. Laboratory, electrocardiogram (ECG) and electroencephalogram (EEG) evaluations were performed. Cerebrospinal fluid and blood samples were taken to evaluate the pharmacokinetics (PK), relative bioavailability and food effect. TAK-071 was safe and well tolerated, and no deaths or serious adverse events occurred. TAK-071 demonstrated a long mean (% coefficient of variation) half-life of 46.3 (25.2%) to 60.5 (51.5%) hours and excellent brain penetration following oral dosing. Coadministration with donepezil had no impact on the PK of either drug. There was no food effect on systemic exposure. Quantitative EEG analysis revealed that TAK-071 40-80 mg increased power in the 7-9 Hz range in the posterior electrode group with eyes open and 120-160 mg doses increased power in the 16-18 Hz range and reduced power in the 2-4 Hz range in central-posterior areas with eyes open and eyes closed. Functional connectivity was significantly reduced after TAK-071 at high doses and was enhanced with coadministration of donepezil under the eyes-closed condition. PK and safety profiles of TAK-071 were favorable, including those exceeding expected pharmacologically active doses based on preclinical data. When administered without donepezil TAK-071 was largely free of cholinergic adverse effects. Further clinical evaluation of TAK-071 is warranted.
Author Gevorkyan, Hakop
Martenyi, Ferenc
Mamashli, Fahimeh
Buhl, Derek L.
Rosen, Laura
Simen, Arthur A.
Khudyakov, Polyna
Yin, Wei
Volfson, Dmitri
AuthorAffiliation 3 Prothena Biosciences South San Francisco CA USA
4 California Clinical Trials Medical Group, in affiliation with Parexel International Glendale CA USA
1 Takeda Pharmaceutical Company Ltd Cambridge MA USA
2 Signal Insights, LLC Cambridge MA USA
AuthorAffiliation_xml – name: 1 Takeda Pharmaceutical Company Ltd Cambridge MA USA
– name: 3 Prothena Biosciences South San Francisco CA USA
– name: 4 California Clinical Trials Medical Group, in affiliation with Parexel International Glendale CA USA
– name: 2 Signal Insights, LLC Cambridge MA USA
Author_xml – sequence: 1
  givenname: Wei
  surname: Yin
  fullname: Yin, Wei
  organization: Takeda Pharmaceutical Company Ltd
– sequence: 2
  givenname: Fahimeh
  surname: Mamashli
  fullname: Mamashli, Fahimeh
  organization: Signal Insights, LLC
– sequence: 3
  givenname: Derek L.
  surname: Buhl
  fullname: Buhl, Derek L.
  organization: Takeda Pharmaceutical Company Ltd
– sequence: 4
  givenname: Polyna
  surname: Khudyakov
  fullname: Khudyakov, Polyna
  organization: Takeda Pharmaceutical Company Ltd
– sequence: 5
  givenname: Dmitri
  surname: Volfson
  fullname: Volfson, Dmitri
  organization: Takeda Pharmaceutical Company Ltd
– sequence: 6
  givenname: Ferenc
  surname: Martenyi
  fullname: Martenyi, Ferenc
  organization: Prothena Biosciences
– sequence: 7
  givenname: Hakop
  surname: Gevorkyan
  fullname: Gevorkyan, Hakop
  organization: California Clinical Trials Medical Group, in affiliation with Parexel International
– sequence: 8
  givenname: Laura
  surname: Rosen
  fullname: Rosen, Laura
  organization: Takeda Pharmaceutical Company Ltd
– sequence: 9
  givenname: Arthur A.
  orcidid: 0000-0002-2844-1516
  surname: Simen
  fullname: Simen, Arthur A.
  email: arthur.simen@takeda.com
  organization: Takeda Pharmaceutical Company Ltd
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34240455$$D View this record in MEDLINE/PubMed
BookMark eNp1kcFu1DAQhi1URLcLB14A-QjSprWdOIkvSO1qKYgikChny_GOWRfHTm1n0d54BI48H09C6C4VHPBlZM2nb2b0n6AjHzwg9JSSUzq9s04Pp7QSDX-AZrSsecEo40doRkpSF5xxeoxOUrohhJa05o_QcVmxilScz9CPj8pA3i3wsFGxVzp8sR6y1Qkrv8a3o_LZZpXtFvBqdYn7sB7d9A0eB4Ovz9_-_PadNHSBFfZhCw73Y9IqWm81fkdxBA1DDhEPIdk7iXIupAxx6h9cIS6w9XgDyuXNDqexuwGd02P00CiX4MmhztGnV6vr5evi6v3lm-X5VaErynmxNo0qW9ExUzIlWqYZFaxqGKFADIiatYw1dWsUFe10qdDQmE61XJRVSUTVlXP0cu8dxq6HtQafo3JyiLZXcSeDsvLfjrcb-TlspWCCEt5MgucHQQy3I6Qse5s0OKc8hDFJxjlhdS2mkXP0Yo_qGFKKYO7HUCJ_JymnJOVdkhP77O-97sk_0U3A2R74ah3s_m-SF8sPe-UvQwutTA
CitedBy_id crossref_primary_10_1007_s10286_024_01016_5
crossref_primary_10_3390_molecules27061816
crossref_primary_10_1021_acs_jmedchem_4c00293
crossref_primary_10_1038_s41582_023_00891_2
crossref_primary_10_1007_s11172_023_3846_1
Cites_doi 10.1016/j.clinph.2004.04.029
10.1016/S0197-4580(00)00090-7
10.1155/2018/5174815
10.1016/j.neuroimage.2011.01.055
10.1016/j.ijpsycho.2020.08.012
10.1038/nrd2760
10.1021/acs.jmedchem.6b00544
10.1177/00912700122012689
10.1016/j.neuroscience.2019.07.003
10.2741/4587
10.1002/trc2.12093
10.1038/s41386-018-0168-8
10.1007/s12640-016-9672-y
10.1016/j.neuron.2015.09.034
10.3389/fphar.2019.00943
10.1016/j.jneumeth.2007.02.011
10.1002/mds.23932
10.1371/journal.pone.0207969
10.1007/s10548-017-0608-5
10.1007/s00213-019-05354-5
10.1124/jpet.117.243774
10.1038/s41598-019-44403-z
10.1016/j.neurobiolaging.2020.01.012
10.1002/(SICI)1097-0193(1999)8:4<194::AID-HBM4>3.0.CO;2-C
10.1007/s10548-017-0546-2
10.1021/acs.jmedchem.7b00597
ContentType Journal Article
Copyright 2021 The Authors. published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Copyright_xml – notice: 2021 The Authors. published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
– notice: 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOI 10.1111/bcp.14975
DatabaseName Wiley Online Library Open Access
Wiley Online Library Free Content
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: 24P
  name: Open Access: Wiley-Blackwell Open Access Journals
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Yin et al
EISSN 1365-2125
EndPage 612
ExternalDocumentID 10_1111_bcp_14975
34240455
BCP14975
Genre article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Takeda Pharmaceuticals, Cambridge Massachusetts
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
AOIJS
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FIJ
FUBAC
G-S
G.N
GODZA
GX1
H.X
HF~
HGLYW
HYE
HZI
HZ~
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
RPM
RX1
SUPJJ
TEORI
TR2
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAMNL
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c4155-df7a389b2f32a982c219247201e0fe962822768fa198afe9ce7fba859343094b3
IEDL.DBID 24P
ISSN 0306-5251
IngestDate Tue Sep 17 21:26:29 EDT 2024
Wed Dec 04 10:03:07 EST 2024
Fri Dec 06 04:13:22 EST 2024
Tue Aug 27 13:45:53 EDT 2024
Sat Aug 24 00:57:50 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords phase I
Parkinson's disease
pharmacokinetic-pharmacodynamic
electrophysiology
Alzheimer's disease
Language English
License Attribution-NonCommercial-NoDerivs
2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
http://creativecommons.org/licenses/by-nc-nd/4.0
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4155-df7a389b2f32a982c219247201e0fe962822768fa198afe9ce7fba859343094b3
Notes Funding information
The authors confirm that the Primary Investigator for this study was Dr Hakop Gevorkyan and that he had direct clinical responsibility for subjects.
Takeda Pharmaceuticals, Cambridge Massachusetts
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-News-3
content type line 23
Funding information Takeda Pharmaceuticals, Cambridge Massachusetts
ORCID 0000-0002-2844-1516
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbcp.14975
PMID 34240455
PQID 2550266959
PQPubID 23479
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9291057
proquest_miscellaneous_2550266959
crossref_primary_10_1111_bcp_14975
pubmed_primary_34240455
wiley_primary_10_1111_bcp_14975_BCP14975
PublicationCentury 2000
PublicationDate February 2022
PublicationDateYYYYMMDD 2022-02-01
PublicationDate_xml – month: 02
  year: 2022
  text: February 2022
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Hoboken
PublicationTitle British journal of clinical pharmacology
PublicationTitleAlternate Br J Clin Pharmacol
PublicationYear 2022
Publisher John Wiley and Sons Inc
Publisher_xml – name: John Wiley and Sons Inc
References 2018; 364
2019; 9
2017; 60
2019; 10
2000; 21
2007; 163
2019; 14
2011; 55
1999; 8
2018; 23
2016; 59
2001; 41
2020; 6
2017; 31
2018; 2018
2004; 115
2019; 44
2015; 88
2020; 90
2020; 237
2009; 8
2011; 26
2019; 414
2020; 158
2018; 31
2019; 176
e_1_2_13_25_1
e_1_2_13_24_1
e_1_2_13_27_1
e_1_2_13_26_1
e_1_2_13_21_1
e_1_2_13_20_1
e_1_2_13_23_1
Alexander SPH (e_1_2_13_16_1) 2019; 176
e_1_2_13_22_1
e_1_2_13_9_1
e_1_2_13_8_1
e_1_2_13_7_1
e_1_2_13_6_1
e_1_2_13_17_1
e_1_2_13_18_1
e_1_2_13_19_1
e_1_2_13_13_1
e_1_2_13_14_1
e_1_2_13_15_1
e_1_2_13_10_1
e_1_2_13_11_1
e_1_2_13_12_1
e_1_2_13_5_1
e_1_2_13_4_1
e_1_2_13_3_1
e_1_2_13_2_1
e_1_2_13_28_1
References_xml – volume: 163
  start-page: 161
  issue: 1
  year: 2007
  end-page: 175
  article-title: Nonparametric statistical testing of coherence differences
  publication-title: J Neurosci Methods
– volume: 90
  start-page: 43
  year: 2020
  end-page: 59
  article-title: Resting‐state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT‐preAD study
  publication-title: Neurobiol Aging
– volume: 55
  start-page: 1548
  issue: 4
  year: 2011
  end-page: 1565
  article-title: An improved index of phase‐synchronization for electrophysiological data in the presence of volume‐conduction, noise and sample‐size bias
  publication-title: Neuroimage
– volume: 31
  start-page: 162
  issue: 1
  year: 2017
  end-page: 168
  article-title: Concentration of donepezil in the cerebrospinal fluid of AD patients: Evaluation of dosage sufficiency in standard treatment strategy
  publication-title: Neurotox Res
– volume: 364
  start-page: 28
  issue: 1
  year: 2018
  end-page: 37
  article-title: An approach to discovering novel muscarinic M1 receptor positive allosteric modulators with potent cognitive improvement and minimized gastrointestinal dysfunction
  publication-title: J Pharmacol Exp Ther
– volume: 14
  issue: 3
  year: 2019
  article-title: TAK‐071, a muscarinic M1 receptor positive allosteric modulator, attenuates scopolamine‐induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys
  publication-title: PLoS One
– volume: 60
  start-page: 6649
  issue: 15
  year: 2017
  end-page: 6663
  article-title: Design and synthesis of gamma‐ and delta‐lactam M1 positive allosteric modulators (PAMs): Convulsion and cholinergic toxicity of an M1‐selective PAM with weak agonist activity
  publication-title: J Med Chem
– volume: 8
  start-page: 194
  issue: 4
  year: 1999
  end-page: 208
  article-title: Measuring phase synchrony in brain signals
  publication-title: Hum Brain Mapp
– volume: 2018
  year: 2018
  article-title: Systematic review on resting‐state EEG for Alzheimer's disease diagnosis and progression assessment
  publication-title: Dis Markers
– volume: 59
  start-page: 6313
  year: 2016
  end-page: 6328
  article-title: Discovery of the potent and selective M1 PAM‐agonist N‐[(3R,4S)‐3‐hydroxytetrahydro‐2H‐pyran‐4‐yl]‐5‐methyl‐4‐[4‐(1,3‐thiazol‐4‐yl)ben zyl]pyridine‐2‐carboxamide (PF‐06767832): Evaluation of efficacy and cholinergic side effects
  publication-title: J Med Chem
– volume: 10
  start-page: 943
  year: 2019
  article-title: The concentration of memantine in the cerebrospinal fluid of Alzheimer's disease patients and its consequence to oxidative stress biomarkers
  publication-title: Front Pharmacol
– volume: 21
  start-page: 11
  issue: 1
  year: 2000
  end-page: 17
  article-title: Choline acetyltransferase activity and cognitive domain scores of Alzheimer's patients
  publication-title: Neurobiol Aging
– volume: 158
  start-page: 259
  year: 2020
  end-page: 270
  article-title: Resting‐state electroencephalographic delta rhythms may reflect global cortical arousal in healthy old seniors and patients with Alzheimer's disease dementia
  publication-title: Int J Psychophysiol
– volume: 414
  start-page: 60
  year: 2019
  end-page: 76
  article-title: In vivo pharmacological comparison of TAK‐071, a positive allosteric modulator of muscarinic M1 receptor, and xanomeline, an agonist of muscarinic M1/M4 receptor, in rodents
  publication-title: Neuroscience
– volume: 6
  year: 2020
  article-title: Safety, pharmacokinetics, and pharmacodynamics of Gln‐1062, a prodrug of galantamine
  publication-title: Alzheimers Dement (N Y)
– volume: 31
  start-page: 101
  issue: 1
  year: 2018
  end-page: 116
  article-title: EEG signatures of dynamic functional network connectivity states
  publication-title: Brain Topogr
– volume: 26
  start-page: 2496
  issue: 14
  year: 2011
  end-page: 2503
  article-title: The interplay of cholinergic function, attention, and falls in Parkinson's disease
  publication-title: Mov Disord
– volume: 44
  start-page: 950
  issue: 5
  year: 2019
  end-page: 960
  article-title: TAK‐071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects
  publication-title: Neuropsychopharmacology
– volume: 23
  start-page: 183
  issue: 1
  year: 2018
  end-page: 220
  article-title: EEG and ERP biomarkers of Alzheimer's disease: a critical review
  publication-title: Front Biosci (Landmark Ed)
– volume: 115
  start-page: 2292
  issue: 10
  year: 2004
  end-page: 2307
  article-title: Identifying true brain interaction from EEG data using the imaginary part of coherency
  publication-title: Clin Neurophysiol
– volume: 41
  start-page: 1082
  issue: 10
  year: 2001
  end-page: 1090
  article-title: Pharmacokinetic‐pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease
  publication-title: J Clin Pharmacol
– volume: 9
  start-page: 7942
  issue: 1
  year: 2019
  article-title: Permutation statistics for connectivity analysis between regions of interest in EEG and MEG data
  publication-title: Sci Rep
– volume: 176
  start-page: S21
  issue: Suppl 1
  year: 2019
  end-page: S141
  article-title: THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors
  publication-title: Br J Pharmacol
– volume: 88
  start-page: 220
  issue: 1
  year: 2015
  end-page: 235
  article-title: Rhythms for cognition: Communication through coherence
  publication-title: Neuron
– volume: 237
  start-page: 137
  issue: 1
  year: 2020
  end-page: 153
  article-title: Rescuing the attentional performance of rats with cholinergic losses by the M1 positive allosteric modulator TAK‐071
  publication-title: Psychopharmacology (Berl)
– volume: 31
  start-page: 380
  issue: 3
  year: 2018
  end-page: 391
  article-title: Brain networks are independently modulated by donepezil, sleep, and sleep deprivation
  publication-title: Brain Topogr
– volume: 8
  start-page: 41
  issue: 1
  year: 2009
  end-page: 54
  article-title: Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
  publication-title: Nat Rev Drug Discov
– ident: e_1_2_13_12_1
  doi: 10.1016/j.clinph.2004.04.029
– ident: e_1_2_13_2_1
  doi: 10.1016/S0197-4580(00)00090-7
– ident: e_1_2_13_26_1
  doi: 10.1155/2018/5174815
– ident: e_1_2_13_13_1
  doi: 10.1016/j.neuroimage.2011.01.055
– ident: e_1_2_13_23_1
  doi: 10.1016/j.ijpsycho.2020.08.012
– ident: e_1_2_13_7_1
  doi: 10.1038/nrd2760
– ident: e_1_2_13_5_1
  doi: 10.1021/acs.jmedchem.6b00544
– ident: e_1_2_13_20_1
  doi: 10.1177/00912700122012689
– ident: e_1_2_13_9_1
  doi: 10.1016/j.neuroscience.2019.07.003
– ident: e_1_2_13_25_1
  doi: 10.2741/4587
– ident: e_1_2_13_19_1
  doi: 10.1002/trc2.12093
– ident: e_1_2_13_10_1
  doi: 10.1038/s41386-018-0168-8
– volume: 176
  start-page: S21
  issue: 1
  year: 2019
  ident: e_1_2_13_16_1
  article-title: THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors
  publication-title: Br J Pharmacol
  contributor:
    fullname: Alexander SPH
– ident: e_1_2_13_22_1
  doi: 10.1007/s12640-016-9672-y
– ident: e_1_2_13_28_1
  doi: 10.1016/j.neuron.2015.09.034
– ident: e_1_2_13_21_1
  doi: 10.3389/fphar.2019.00943
– ident: e_1_2_13_15_1
  doi: 10.1016/j.jneumeth.2007.02.011
– ident: e_1_2_13_3_1
  doi: 10.1002/mds.23932
– ident: e_1_2_13_8_1
  doi: 10.1371/journal.pone.0207969
– ident: e_1_2_13_17_1
  doi: 10.1007/s10548-017-0608-5
– ident: e_1_2_13_11_1
  doi: 10.1007/s00213-019-05354-5
– ident: e_1_2_13_6_1
  doi: 10.1124/jpet.117.243774
– ident: e_1_2_13_14_1
  doi: 10.1038/s41598-019-44403-z
– ident: e_1_2_13_24_1
  doi: 10.1016/j.neurobiolaging.2020.01.012
– ident: e_1_2_13_18_1
  doi: 10.1002/(SICI)1097-0193(1999)8:4<194::AID-HBM4>3.0.CO;2-C
– ident: e_1_2_13_27_1
  doi: 10.1007/s10548-017-0546-2
– ident: e_1_2_13_4_1
  doi: 10.1021/acs.jmedchem.7b00597
SSID ssj0013165
Score 2.4526708
Snippet Aims TAK‐071 is a muscarinic M1 receptor positive allosteric modulator designed to have low cooperativity with acetylcholine. This was a first‐in‐human study...
TAK-071 is a muscarinic M receptor positive allosteric modulator designed to have low cooperativity with acetylcholine. This was a first-in-human study to...
AIMSTAK-071 is a muscarinic M1 receptor positive allosteric modulator designed to have low cooperativity with acetylcholine. This was a first-in-human study to...
SourceID pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 600
SubjectTerms Alzheimer's disease
Donepezil - adverse effects
Dose-Response Relationship, Drug
Double-Blind Method
Electroencephalography
electrophysiology
Healthy Volunteers
Humans
Original
Parkinson's disease
pharmacokinetic‐pharmacodynamic
phase I
Receptor, Muscarinic M1 - agonists
Title Safety, pharmacokinetics and quantitative EEG modulation of TAK‐071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbcp.14975
https://www.ncbi.nlm.nih.gov/pubmed/34240455
https://search.proquest.com/docview/2550266959
https://pubmed.ncbi.nlm.nih.gov/PMC9291057
Volume 88
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3BbtQwELVKuXCpoFC6QNGAUNXDRtp14iQWp9JuqUCgFWyl3iLbsdUK6izNBmlvfALHfh9fwoyT3e2qQuISRYljJXkZ-00884axN7HOUy2lilJZiigxmYv0IDcRF3bghIlxzglRvp_T07Pkw7k432BvF7kwrT7E8ocbWUYYr8nAla5vGbk2UzRzmYl77D7SmpTKF_BkvFpCGIY6ksSJ0dsSw05WiMJ4lpeuT0Z3GObdQMnbBDbMQCcP2VZHHeGwxfoR27B-m-2PW-3peR8mq1Squg_7MF6pUs8fs5uvytkZNpt2h7_hG6CmoHwJPxrlQ7oZDn4wGr2Hq6rsCntB5WBy-PHPr9_IE_qgwFc_7Xe4amqjaPnHwKch4Lhpp-i-QxsEhp3Qgj6JMOD5rq_qug-XHtrMyznUjaZ_QPUTdnYymhydRl1ZhsgQ-4hKlymkOZq7mCuZc8PJicsQVYTXypQCU9GJcWooc3wyaWzmtCJdtSRGZ1LHO2zTV97uMigVT-PE5Bl36KeXODUi2U-l1UaKgVZZj71e4FNMW_WNYuG1IIhFALHHXi2QK9A2aMFDeVs1dYHuErqYqRSyx562SC67iRPkMonAq7M1jJcNSHd7_Yy_vAj628goqTpyjx2Er-Hfd1a8OxqHnWf_3_Q5e8ApwyIEhr9gm7Prxu4h75npl-H7xu3xF_4XtuACbA
link.rule.ids 230,314,780,784,885,1375,11562,27924,27925,46052,46294,46476,46718
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKOcCF92N5DghVHDbVxnla4lLKloU-tIKt1EsV2Y4jqtJk2SRIy4mfwJHfxy9hxkl2u1RIiFuUOJYtz9jf2N98ZuyFp-JQCSGdUKSB4-soc9Qg1g4PzCALtIdrjmX5HoSjQ__9UXC0xl51uTCNPsRiw408w87X5OC0IX3Oy5Weop-LKLjELqO7u0ToevOBL88QXHuRJIFiDLcCt9UVIh7P4tfV1egCxLzIlDyPYO0StHOdHXeNb5gnp5t1pTb1tz90Hf-3dzfYtRabwlZjTDfZmslvsY1xI24978NkmatV9mEDxkvZ6_lt9vOjzEyFxabt61NsBBUFmafwpZa5zWfD2RWGw7dwVqTtzWFQZDDZ2v31_QcCkT5IyIuv5jOc1aWWdL6kYd8FnJjNtCpm0LDMsBJiDJDKA35v6ypmfTjJoUntnENZK9pkKu-ww53hZHvktPc-OJrgjZNmkUQcpXjmcSlirjlFiRGaDdqPESExXzFKyqQrYuyZ0CbKlCThNt_DaFV5d9l6XuTmPoNU8tDzdRzxbOCHKa69GE2EwigtgoGSUY8978Y_mTbyHkkXFuEIJHYEeuxZZxkJOh-dqMjcFHWZYDyGMWwoAtFj9xpLWVTj-QiW_AD_jlZsaFGAhL1Xv-Qnn6zAN0JWun65x15aE_l7y5LX22P78ODfiz5lV0aT_b1k793B7kN2lVM6h2WhP2Lr1aw2jxFkVeqJ9aXfG8Ulqw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKkRAX3o_lOSBUcdhUu87T4lTaXQqFagVbqQekyHZstWrrhE2CtJz4CRz5ffwSxk6y26VCQtyieGzZ8oz9jT3zmZAXvkgiwRj3IpaFXiBj7YlBIj0aqoEOpY97jovy3Y92D4J3h-HhGnnV5cI0_BCLAzdrGW69tgZeZPqckQtZoJmzOLxELgcRZZY4f-cjXV4hDN07khYTo7cVDltaIRvGs6i6uhldQJgXAyXPA1i3A42vk89d35vAk5PNuhKb8tsftI7_Obgb5FqLTGGrUaWbZE2ZW2Rj0lBbz_swXWZqlX3YgMmS9Hp-m_z8xLWqUKxof59gH6wocJPBl5obl82GayuMRm_gLM_ad8Mg1zDd2vv1_QfCkD5wMPlXdQpndSm5vV2S8GEIuCyrospn0MSYYSM2XsByPGB521Y-68OxgSaxcw5lLewRU3mHHIxH0-1dr331wZMW3HiZjjmiKEG1TzlLqKTWR4xRaVB7FIts3Cv6SJoPWYIjY1LFWnBL2xb46KsK_y5ZN7lR9wlknEZ-IJOY6kEQZbjzoi8RMSUkCweCxz3yvJv-tGjIPdLOKcIZSN0M9MizTjFSND17n8KNyusyRW8MPdiIhaxH7jWKsmjGDxAqBSHWjldUaCFgab1XS8zxkaP3RsBqH1_ukZdOQ_7es_T19sR9PPh30afkymRnnL5_u7_3kFylNpfDhaA_IuvVrFaPEWFV4omzpN-d3iRa
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety%2C+pharmacokinetics+and+quantitative+EEG+modulation+of+TAK%E2%80%90071%2C+a+novel+muscarinic+M1+receptor+positive+allosteric+modulator%2C+in+healthy+subjects&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Yin%2C+Wei&rft.au=Mamashli%2C+Fahimeh&rft.au=Buhl%2C+Derek+L.&rft.au=Khudyakov%2C+Polyna&rft.date=2022-02-01&rft.issn=0306-5251&rft.eissn=1365-2125&rft.volume=88&rft.issue=2&rft.spage=600&rft.epage=612&rft_id=info:doi/10.1111%2Fbcp.14975&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_bcp_14975
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon